Anavex Life Sciences AVXL

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

• GlobeNewswire Inc. 5 oct

  ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Qfin Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QFIN

  Rosen Law Firm has filed class action lawsuits against Qfin Holdings, Inc. and Anavex Life Sciences Corp. on behalf of investors who purchased securities during specified periods. The Qfin lawsuit alleges defendants made false statements about business resilience and downplayed regulatory impacts. Investors have until November 30, 2026 to move the court to serve as lead plaintiff.

  

• GlobeNewswire Inc. 5 oct

  ANAVEX CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. and Encourages Investors to Contact the Firm

  A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and its executives violated federal securities laws by making false and misleading statements regarding adequate internal controls, understating regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresenting the company's business and prospects. Investors who purchased Anavex securities between November 26, 2025 and August 28, 2026 may be eligible to participate in the lawsuit.

  

• GlobeNewswire Inc. 2 oct

  ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

  Rosen Law Firm has filed a class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that the company made false and misleading statements regarding adequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented its business operations and prospects. Investors have until November 30, 2026 to move the court to serve as lead plaintiff.

  

• GlobeNewswire Inc. 1 oct

  Bronstein, Gewirtz & Grossman LLC Urges Anavex Life Sciences Corp. Investors to Act: Class Action Filed Alleging Investor Harm

  A class action lawsuit has been filed against Anavex Life Sciences Corp. alleging securities fraud. The complaint claims the company made false statements about its business operations, lacked adequate internal controls, and understated regulatory challenges related to misconduct by former CEO Christopher Missling. The class period covers November 26, 2025 to August 28, 2026, and investors have until November 30, 2026 to request lead plaintiff status.

  

• GlobeNewswire Inc. 30 sept

  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. (AVXL)

  A securities class action lawsuit has been filed against Anavex Life Sciences Corp. (AVXL) for allegedly failing to disclose inadequate internal controls and regulatory challenges stemming from former CEO misconduct. The lawsuit covers securities purchased between November 26, 2025 and August 28, 2026. Investors have until November 30, 2026 to file as lead plaintiffs.